Retrovirally transduced human dendritic cells express a normal phenotype and potent T-cell stimulatory capacity

Paul Szabolcs, H. F. Gallardo, David H. Ciocon, Michel Sadelain, James W. Young

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Dendritic cells are attractive candidates for vaccine-based immunotherapy because of their potential to function as natural adjuvants for poorly immunogenic proteins derived from tumors or microbes. In this study, we evaluated the feasibility and consequences of introducing foreign genetic material by retroviral vectors into dendritic cell progenitors. Proliferating human bone marrow and cord blood CD34+ cells were infected by retrovital vectors encoding the murine CD2 surface antigen. Mean transduction efficiency in dendritic cells was 11.5% from bone marrow and 21.2% from cord blood progenitors. Transduced or untransduced dendritic cell progeny expressed comparable levels of HLA-DR, CD83, CD1a, CD80, CD86, S100, and p55 antigens. Granulocytes, macrophages, and dendritic cells were equally represented among the transduced and mock-transduced cells, thus showing no apparent alteration in the differentiation of transduced CD34+ precursors. The T-cell stimulatory capacity of retrovirally modified and purified mCD2-positive allogeneic or nominal antigen-pulsed autologous dendritic cells was comparable with that of untransduced dendritic cells, human CD34+ dendritic cell progenitors can therefore be efficiently transduced using retroviral vectors and can differentiate into potent immunostimulatory dendritic cells without compromising their T-cell stimulators, capacity or the expression of critical costimulatory molecules and phenotypic markers. These results support ongoing efforts to develop genetically modified dendritic cells for immunotherapy.

Original languageEnglish (US)
Pages (from-to)2160-2167
Number of pages8
JournalBlood
Volume90
Issue number6
StatePublished - Sep 15 1997
Externally publishedYes

Fingerprint

T-cells
Dendritic Cells
T-Lymphocytes
Phenotype
Fetal Blood
Immunotherapy
CD2 Antigens
Bone
Blood
Bone Marrow
Macrophages
Autoantigens
HLA-DR Antigens
Surface Antigens
Granulocytes
Tumors
Blood Cells
Vaccines
Antigens
Molecules

ASJC Scopus subject areas

  • Hematology

Cite this

Szabolcs, P., Gallardo, H. F., Ciocon, D. H., Sadelain, M., & Young, J. W. (1997). Retrovirally transduced human dendritic cells express a normal phenotype and potent T-cell stimulatory capacity. Blood, 90(6), 2160-2167.

Retrovirally transduced human dendritic cells express a normal phenotype and potent T-cell stimulatory capacity. / Szabolcs, Paul; Gallardo, H. F.; Ciocon, David H.; Sadelain, Michel; Young, James W.

In: Blood, Vol. 90, No. 6, 15.09.1997, p. 2160-2167.

Research output: Contribution to journalArticle

Szabolcs, P, Gallardo, HF, Ciocon, DH, Sadelain, M & Young, JW 1997, 'Retrovirally transduced human dendritic cells express a normal phenotype and potent T-cell stimulatory capacity', Blood, vol. 90, no. 6, pp. 2160-2167.
Szabolcs, Paul ; Gallardo, H. F. ; Ciocon, David H. ; Sadelain, Michel ; Young, James W. / Retrovirally transduced human dendritic cells express a normal phenotype and potent T-cell stimulatory capacity. In: Blood. 1997 ; Vol. 90, No. 6. pp. 2160-2167.
@article{9d25dba7460441efa9f525b1a0263edb,
title = "Retrovirally transduced human dendritic cells express a normal phenotype and potent T-cell stimulatory capacity",
abstract = "Dendritic cells are attractive candidates for vaccine-based immunotherapy because of their potential to function as natural adjuvants for poorly immunogenic proteins derived from tumors or microbes. In this study, we evaluated the feasibility and consequences of introducing foreign genetic material by retroviral vectors into dendritic cell progenitors. Proliferating human bone marrow and cord blood CD34+ cells were infected by retrovital vectors encoding the murine CD2 surface antigen. Mean transduction efficiency in dendritic cells was 11.5{\%} from bone marrow and 21.2{\%} from cord blood progenitors. Transduced or untransduced dendritic cell progeny expressed comparable levels of HLA-DR, CD83, CD1a, CD80, CD86, S100, and p55 antigens. Granulocytes, macrophages, and dendritic cells were equally represented among the transduced and mock-transduced cells, thus showing no apparent alteration in the differentiation of transduced CD34+ precursors. The T-cell stimulatory capacity of retrovirally modified and purified mCD2-positive allogeneic or nominal antigen-pulsed autologous dendritic cells was comparable with that of untransduced dendritic cells, human CD34+ dendritic cell progenitors can therefore be efficiently transduced using retroviral vectors and can differentiate into potent immunostimulatory dendritic cells without compromising their T-cell stimulators, capacity or the expression of critical costimulatory molecules and phenotypic markers. These results support ongoing efforts to develop genetically modified dendritic cells for immunotherapy.",
author = "Paul Szabolcs and Gallardo, {H. F.} and Ciocon, {David H.} and Michel Sadelain and Young, {James W.}",
year = "1997",
month = "9",
day = "15",
language = "English (US)",
volume = "90",
pages = "2160--2167",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "6",

}

TY - JOUR

T1 - Retrovirally transduced human dendritic cells express a normal phenotype and potent T-cell stimulatory capacity

AU - Szabolcs, Paul

AU - Gallardo, H. F.

AU - Ciocon, David H.

AU - Sadelain, Michel

AU - Young, James W.

PY - 1997/9/15

Y1 - 1997/9/15

N2 - Dendritic cells are attractive candidates for vaccine-based immunotherapy because of their potential to function as natural adjuvants for poorly immunogenic proteins derived from tumors or microbes. In this study, we evaluated the feasibility and consequences of introducing foreign genetic material by retroviral vectors into dendritic cell progenitors. Proliferating human bone marrow and cord blood CD34+ cells were infected by retrovital vectors encoding the murine CD2 surface antigen. Mean transduction efficiency in dendritic cells was 11.5% from bone marrow and 21.2% from cord blood progenitors. Transduced or untransduced dendritic cell progeny expressed comparable levels of HLA-DR, CD83, CD1a, CD80, CD86, S100, and p55 antigens. Granulocytes, macrophages, and dendritic cells were equally represented among the transduced and mock-transduced cells, thus showing no apparent alteration in the differentiation of transduced CD34+ precursors. The T-cell stimulatory capacity of retrovirally modified and purified mCD2-positive allogeneic or nominal antigen-pulsed autologous dendritic cells was comparable with that of untransduced dendritic cells, human CD34+ dendritic cell progenitors can therefore be efficiently transduced using retroviral vectors and can differentiate into potent immunostimulatory dendritic cells without compromising their T-cell stimulators, capacity or the expression of critical costimulatory molecules and phenotypic markers. These results support ongoing efforts to develop genetically modified dendritic cells for immunotherapy.

AB - Dendritic cells are attractive candidates for vaccine-based immunotherapy because of their potential to function as natural adjuvants for poorly immunogenic proteins derived from tumors or microbes. In this study, we evaluated the feasibility and consequences of introducing foreign genetic material by retroviral vectors into dendritic cell progenitors. Proliferating human bone marrow and cord blood CD34+ cells were infected by retrovital vectors encoding the murine CD2 surface antigen. Mean transduction efficiency in dendritic cells was 11.5% from bone marrow and 21.2% from cord blood progenitors. Transduced or untransduced dendritic cell progeny expressed comparable levels of HLA-DR, CD83, CD1a, CD80, CD86, S100, and p55 antigens. Granulocytes, macrophages, and dendritic cells were equally represented among the transduced and mock-transduced cells, thus showing no apparent alteration in the differentiation of transduced CD34+ precursors. The T-cell stimulatory capacity of retrovirally modified and purified mCD2-positive allogeneic or nominal antigen-pulsed autologous dendritic cells was comparable with that of untransduced dendritic cells, human CD34+ dendritic cell progenitors can therefore be efficiently transduced using retroviral vectors and can differentiate into potent immunostimulatory dendritic cells without compromising their T-cell stimulators, capacity or the expression of critical costimulatory molecules and phenotypic markers. These results support ongoing efforts to develop genetically modified dendritic cells for immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0030866293&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030866293&partnerID=8YFLogxK

M3 - Article

VL - 90

SP - 2160

EP - 2167

JO - Blood

JF - Blood

SN - 0006-4971

IS - 6

ER -